伊诺维奥制药 INO 深 沪
已收盘 08-15 16:00:00 美东时间
1.86
+0.240
+14.81%
华盛通- 最 高2.0793
- 今 开1.75
- 成交量 1167.17万股
- 最 低 1.75
- 昨 收 1.62
- 总市值 6821.44万
- 52周最高 7.71
- 市盈率 静 --
- 换手率 31.83%
- 52周最低 1.30
- 委 比 -42.03%
- 总股本 3667.44万
- 历史最高 405.48
- 量 比 7.14
- 振 幅 20.33%
- 历史最低 1.30
- 每 手 1
- 风险率 1.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inovio rises after promising Q2 results
Inovio Pharmaceuticals (NASDAQ:INO) shares up after the company's net loss lowered in Q2 from the previous year period. The company reported a second quarter 2025 net loss of $0.61 per share, lower th...
08-14 00:06
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Earnings Outlook For Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ:INO) is gearing up to announce its quarterly ear...
08-12 02:02
INOVIO's Announces Peer-reviewed Data From A Retrospective Study Investigating The Long-Term Clinical And Safety Response Of Patients Treated With INO-3107 Were Published Online In The Laryngoscope; INO-3107 Shows Sustained Improvement In RRP Patients, Cutting Surgeries By Over 75% In Year 2
Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete
08-11 20:09
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun Off as an In...
08-01 19:00
Inuvo to Host Second Quarter 2025 Financial Results Conference Call on Thursday, August 7th at 4:15 P.M. ET
Inuvo, Inc. (NYSE American: INUV), a leader in AI AdTech solutions, will host a conference call on August 7, 2025, at 4:15 PM ET to discuss Q2 2025 financial results and provide a business update. Dial-in numbers: 1-800-717-1738 (US) / 1-646-307-1865 (intl). Conference ID: 1148531. Webcast link available. A replay will be accessible through August 21, 2025, via 1-844-512-2921 (US) / 1-412-317-6671 (intl), using the same ID. For more information, ...
07-31 12:15
富士胶片携三大事业参展BIRTV2025
7月23日至26日，第三十二届北京国际广播电影电视展览会（BIRTV2025）在北京中国国际展览中心（朝阳馆）登场。富士胶片（中国）投资有限公司携旗下光电产品...
07-24 14:21
Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025
<p>Inotiv, Inc. announced it will release its fiscal 2025 third-quarter financial results on August 6, 2025, following the market close. A conference call to discuss the results will be held on the same day at 4:30 p.m. ET. Interested parties can join by dialing 1-800-245-3047 (Domestic) or 1-203-518-9765 (International), using the conference ID "INOTIV." A live webcast and replay will be available on the Company’s Investors webpage. Inotiv is a ...
07-23 11:00
SELLAS gains as mid-stage trial for leukemia drug succeeds
SELLAS Life Sciences (NASDAQ:SLS) traded higher in the premarket on Tuesday after the New York-based biotech said that a Phase 2 trial that tested its antitumor agent SLS009 (tambiciclib) as part of a...
07-15 20:22
